In T1D, the pathogenic contribution of MIF was reported by studies demonstrating that antibody and pharmacological inhibitor-mediated MIF neutralization had a prophylactic effect on accelerated diabetes models. The gene discussed is MIF; the disease is type 1 diabetes mellitus.